Phospholipid membranes drive abdominal aortic aneurysm development through stimulating coagulation factor activity

Allen-Redpath, Keith, Aldrovandi, Maceler, Lauder, Sarah N., Gketsopoulou, Anastasia, Tyrrell, Victoria J., Slatter, David A., Andrews, Robert, Watkins, W. John ORCID: https://orcid.org/0000-0003-3262-6588, Atkinson, Georgia, McNeill, Eileen, Gilfedder, Anna, Protty, Majd, Burston, James, Johnson, Sam R. C., Rodrigues, Patricia R. S. ORCID: https://orcid.org/0000-0003-0768-0013, Jones, Dylan O., Lee, Regent, Handa, Ashok, Channon, Keith, Obaji, Samya, Alvarez-Jarreta, Jorge, Krönke, Gerhard, Ackermann, Jochen, Jenkins, P. Vince, Collins, Peter W. ORCID: https://orcid.org/0000-0002-6410-1324 and O'Donnell, Valerie B. ORCID: https://orcid.org/0000-0003-4089-8460 2019. Phospholipid membranes drive abdominal aortic aneurysm development through stimulating coagulation factor activity. Proceedings of the National Academy of Sciences 116 (16) , pp. 8038-8047. 10.1073/pnas.1814409116

Preview

PDF - Published Version Available under License Creative Commons Attribution. Download (21MB) | Preview

Abstract

Abdominal aortic aneurysm (AAA) is an inflammatory vascular disease with high mortality and limited treatment options. How blood lipids regulate AAA development is unknown. Here lipidomics and genetic models demonstrate a central role for procoagulant enzymatically oxidized phospholipids (eoxPL) in regulating AAA. Specifically, through activating coagulation, eoxPL either promoted or inhibited AAA depending on tissue localization. Ang II administration to ApoE−/− mice increased intravascular coagulation during AAA development. Lipidomics revealed large numbers of eoxPL formed within mouse and human AAA lesions. Deletion of eoxPL-generating enzymes (Alox12 or Alox15) or administration of the factor Xa inhibitor rivaroxaban significantly reduced AAA. Alox-deficient mice displayed constitutively dysregulated hemostasis, including a consumptive coagulopathy, characterized by compensatory increase in prothrombotic aminophospholipids (aPL) in circulating cell membranes. Intravenously administered procoagulant PL caused clotting factor activation and depletion, induced a bleeding defect, and significantly reduced AAA development. These data suggest that Alox deletion reduces AAA through diverting coagulation away from the vessel wall due to eoxPL deficiency, instead activating clotting factor consumption and depletion in the circulation. In mouse whole blood, ∼44 eoxPL molecular species formed within minutes of clot initiation. These were significantly elevated with ApoE−/− deletion, and many were absent in Alox−/− mice, identifying specific eoxPL that modulate AAA. Correlation networks demonstrated eoxPL belonged to subfamilies defined by oxylipin composition. Thus, procoagulant PL regulate AAA development through complex interactions with clotting factors. Modulation of the delicate balance between bleeding and thrombosis within either the vessel wall or circulation was revealed that can either drive or prevent disease development.

Item Type:	Article
Date Type:	Publication
Status:	Published
Schools:	Advanced Research Computing @ Cardiff (ARCCA) Medicine
Additional Information:	This open access article is distributed under Creative Commons Attribution License 4.0 (CC BY).
Publisher:	National Academy of Sciences
ISSN:	0027-8424
Funders:	Wellcome Trust
Date of First Compliant Deposit:	29 May 2019
Date of Acceptance:	13 March 2019
Last Modified:	25 Aug 2024 01:06
URI:	https://orca.cardiff.ac.uk/id/eprint/122928

Citation Data

Cited 17 times in Scopus. View in Scopus. Powered By Scopus® Data

Actions (repository staff only)

Edit Item